20.07.2017 • NewsElaine BurridgeTevaCephalon

EU Accuses Teva and Cephalon of Antitrust Breach

(c) Africa Studio/Shutterstock
(c) Africa Studio/Shutterstock

The European Commission has accused Israeli drugmaker Teva and its US subsidiary Cephalon of breaching antitrust rules. Regulators classed an agreement between the companies to delay marketing of a cheaper version of Cephalon’s blockbuster sleep disorder drug, modafinil, as anti-competitive behavior.

Following an investigation, the European Commission said its preliminary findings showed that Cephalon paid Teva not to market the cheaper version of its drug under a ‘pay-for-delay’ deal.

Pennsylvania-based Cephalon, which became part of Teva in October 2011, owned the patents for modafinil but when they expired in the European Economic Area (EEA), Teva launched its cheaper generic version in the UK for a short period of time.

Following a patent infringement lawsuit brought by Cephalon, the companies reached an agreement whereby Teva agreed not to sell its generic modafinil products in the EEA until October 2012. In exchange, the Israeli firmreceived a “substantial transfer of value” from Cephalon through a series of cash payments and various other agreements.

The Commission’s initial view is that the transferred value served as a significant pay-for-delay inducement for Teva not to compete with Cephalon’s modafinil worldwide, which “may have caused substantial harm to EU patients and health service budgets.”

EU Competition Commissioner Margrethe Vestager commented: “Market entry and competition by generic drugs is an essential element to improve the affordability of healthcare. It’s now up to the companies to respond to our concerns.”

Teva could be fined up to 10% of its global revenue if it is found guilty. The firm was fined $1.2 billion by US regulators over the same issue in 2015.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.